Predicting relapse or recurrence of depression: systematic review of prognostic models.

Depressive disorders epidemiology primary care risk assessment statistical methodology

Journal

The British journal of psychiatry : the journal of mental science
ISSN: 1472-1465
Titre abrégé: Br J Psychiatry
Pays: England
ID NLM: 0342367

Informations de publication

Date de publication:
08 2022
Historique:
pubmed: 21 1 2022
medline: 20 7 2022
entrez: 20 1 2022
Statut: ppublish

Résumé

Relapse and recurrence of depression are common, contributing to the overall burden of depression globally. Accurate prediction of relapse or recurrence while patients are well would allow the identification of high-risk individuals and may effectively guide the allocation of interventions to prevent relapse and recurrence. To review prognostic models developed to predict the risk of relapse, recurrence, sustained remission, or recovery in adults with remitted major depressive disorder. We searched the Cochrane Library (current issue); Ovid MEDLINE (1946 onwards); Ovid Embase (1980 onwards); Ovid PsycINFO (1806 onwards); and Web of Science (1900 onwards) up to May 2021. We included development and external validation studies of multivariable prognostic models. We assessed risk of bias of included studies using the Prediction model risk of bias assessment tool (PROBAST). We identified 12 eligible prognostic model studies (11 unique prognostic models): 8 model development-only studies, 3 model development and external validation studies and 1 external validation-only study. Multiple estimates of performance measures were not available and meta-analysis was therefore not necessary. Eleven out of the 12 included studies were assessed as being at high overall risk of bias and none examined clinical utility. Due to high risk of bias of the included studies, poor predictive performance and limited external validation of the models identified, presently available clinical prediction models for relapse and recurrence of depression are not yet sufficiently developed for deploying in clinical settings. There is a need for improved prognosis research in this clinical area and future studies should conform to best practice methodological and reporting guidelines.

Sections du résumé

BACKGROUND
Relapse and recurrence of depression are common, contributing to the overall burden of depression globally. Accurate prediction of relapse or recurrence while patients are well would allow the identification of high-risk individuals and may effectively guide the allocation of interventions to prevent relapse and recurrence.
AIMS
To review prognostic models developed to predict the risk of relapse, recurrence, sustained remission, or recovery in adults with remitted major depressive disorder.
METHOD
We searched the Cochrane Library (current issue); Ovid MEDLINE (1946 onwards); Ovid Embase (1980 onwards); Ovid PsycINFO (1806 onwards); and Web of Science (1900 onwards) up to May 2021. We included development and external validation studies of multivariable prognostic models. We assessed risk of bias of included studies using the Prediction model risk of bias assessment tool (PROBAST).
RESULTS
We identified 12 eligible prognostic model studies (11 unique prognostic models): 8 model development-only studies, 3 model development and external validation studies and 1 external validation-only study. Multiple estimates of performance measures were not available and meta-analysis was therefore not necessary. Eleven out of the 12 included studies were assessed as being at high overall risk of bias and none examined clinical utility.
CONCLUSIONS
Due to high risk of bias of the included studies, poor predictive performance and limited external validation of the models identified, presently available clinical prediction models for relapse and recurrence of depression are not yet sufficiently developed for deploying in clinical settings. There is a need for improved prognosis research in this clinical area and future studies should conform to best practice methodological and reporting guidelines.

Identifiants

pubmed: 35048843
doi: 10.1192/bjp.2021.218
pii: S000712502100218X
doi:

Types de publication

Journal Article Review Systematic Review Research Support, Non-U.S. Gov't

Langues

eng

Sous-ensembles de citation

IM

Pagination

448-458

Subventions

Organisme : Medical Research Council
ID : G0800472
Pays : United Kingdom

Auteurs

Andrew S Moriarty (AS)

Mental Health and Addiction Research Group, Department of Health Sciences, University of York, UK and Hull York Medical School, University of York, UK.

Nicholas Meader (N)

Centre for Reviews and Dissemination, University of York, UK and Cochrane Common Mental Disorders, University of York, UK.

Kym I E Snell (KIE)

Centre for Prognosis Research, School of Medicine, Keele University, UK.

Richard D Riley (RD)

Centre for Prognosis Research, School of Medicine, Keele University, UK.

Lewis W Paton (LW)

Mental Health and Addiction Research Group, Department of Health Sciences, University of York, UK.

Sarah Dawson (S)

Cochrane Common Mental Disorders, University of York, UK and Bristol Medical School, University of Bristol, UK.

Jessica Hendon (J)

Centre for Reviews and Dissemination, University of York, UK and Cochrane Common Mental Disorders, University of York, UK.

Carolyn A Chew-Graham (CA)

School of Medicine, Keele University, UK.

Simon Gilbody (S)

Mental Health and Addiction Research Group, Department of Health Sciences, University of York, UK and Hull York Medical School, University of York, UK.

Rachel Churchill (R)

Centre for Reviews and Dissemination, University of York, UK and Cochrane Common Mental Disorders, University of York, UK.

Robert S Phillips (RS)

Centre for Reviews and Dissemination, University of York, UK.

Shehzad Ali (S)

Mental Health and Addiction Research Group, Department of Health Sciences, University of York, UK and Department of Epidemiology and Biostatistics, Schulich School of Medicine & Dentistry, Western University, Canada.

Dean McMillan (D)

Mental Health and Addiction Research Group, Department of Health Sciences, University of York, UK and Hull York Medical School, University of York, UK.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH